A Radical Court Just Called Trump’s Abortion Bluff
The 5th Circuit Court issued a nationwide injunction blocking the mailing of mifepristone, a drug used in medication abortions and miscarriage care, overturning FDA regulations that allowed telehealth prescriptions. The Supreme Court temporarily stayed the ruling, preserving current access for now. Unlike previous challenges, the Trump administration has supported the review of mifepristone’s safety, despite extensive scientific evidence affirming its safety and efficacy.
- ▪The 5th Circuit’s injunction would prevent mifepristone from being mailed, affecting access even in states where abortion remains legal.
- ▪The Supreme Court issued a temporary stay, allowing mifepristone to continue being mailed while litigation proceeds.
- ▪The Trump administration's FDA announced a review of mifepristone’s safety based on a widely discredited report.
- ▪Over 100 scientific studies have confirmed mifepristone is safe and effective, with safety comparable to common medications like ibuprofen.
- ▪Louisiana challenged the FDA’s telehealth prescribing rule, claiming it relied on flawed or nonexistent data.
Opening excerpt (first ~120 words) tap to expand
Jurisprudence A Radical Court Just Called Trump’s Abortion Bluff By Naomi Cahn and Sonia M. Suter May 04, 20265:32 PM Demonstrators in front of the Supreme Court during oral arguments in FDA v. Alliance for Hippocratic Medicine in March 2024 in Washington. Anna Rose Layden/Getty Images Copy Link Share Share Comment Copy Link Share Share Comment Sign up for Executive Dysfunction, a newsletter that highlights one under-the-radar story each week about how Trump is changing the law—or how the law is pushing back. You’ll also receive updates on the latest from Slate’s Jurisprudence team. On Friday, the archconservative U.S. Court of Appeals for the 5th Circuit issued a stunning nationwide injunction that directly affects one-fourth of all abortions in the United States.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Slate Magazine.
Discussion
0 commentsMore from Slate Magazine
